We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nastech Announces Multi-Compound Agreement with Novo Nordisk
News

Nastech Announces Multi-Compound Agreement with Novo Nordisk

Nastech Announces Multi-Compound Agreement with Novo Nordisk
News

Nastech Announces Multi-Compound Agreement with Novo Nordisk

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nastech Announces Multi-Compound Agreement with Novo Nordisk "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nastech Pharmaceutical Company Inc. has announced that it has entered into a multi-compound, feasibility study agreement with Novo Nordisk A/S with respect to certain Novo Nordisk therapeutic compounds.

"Nastech is honored to be working with Novo Nordisk, a world-leader in therapies for metabolic disease," said Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech.

"Novo Nordisk is known for its ethical standards and has participated in many innovative advances in medical practice."

Advertisement